| The Top 10 Orthopedic Device Companies: Financial | | | | future growth markets effectively, avoid their mistakes, |
| performance, research activities, and growth strategies | | | | and replicate their successes. |
| The global orthopedic market had an estimated $33bn | | | | • Benchmark your performance against the leading |
| size in 2009, an increase of 7.1%. the top 15 orthopedic | | | | orthopedic device companies. |
| companies combined account for 95% of this market. | | | | • Analyze the growth strategies of major players in |
| The orthopedic device industry is highly competitive | | | | the orthopedic industry and learn how their business |
| and has reached maturity, as demonstrated by its | | | | models are planned for the next 3 to 5 years . |
| single digit growth rate. The industry is driven largely by | | | | • Compare performances of the top10 companies |
| incremental innovation and breakthrough product | | | | in the orthopedic market with respect to acquisitions, |
| launches have stalled. Several product lines are also | | | | new product innovation, geography expansion, and |
| facing severe commoditization due to increased | | | | industry challenges. |
| competition. Despite such high levels of competition, the | | | | • Save time, money, and resources on analyzing |
| top 15 companies accounted for 95% of the market in | | | | the performance of leading orthopedic device |
| 2009. The largest device segments are spinal, knee, | | | | companies using this report. |
| and hip implants. The fastest growing segment is | | | | Key findings from this report |
| orthobiologics. | | | | • The global orthopedic market had an estimated |
| The report provides detailed profiles of the top 10 | | | | $33bn size in 2009, a Y-o-Y increase of 7.1%. The |
| orthopedic device companies and brief profiles of five | | | | market is moderately dependent on macroeconomic |
| other major players. It elucidates trends associated | | | | trends and demographics. |
| with companies that develop, manufacture, and market | | | | • In 2009, the market growth was adversely |
| orthopedic devices. Detailed profiles contain | | | | affected by patient deferral of orthopedic procedures |
| descriptions of products, financial performance, and | | | | and increased pricing pressure from buyers. Market |
| growth strategies together with SWOT analyses. For | | | | performance was also considerably impacted by |
| each company analysis is based on: | | | | currency fluctuations, owing to a strengthening US |
| • Each company's consolidated and segmental | | | | dollar. This is due to the fact that majority of |
| financial performance; | | | | orthopedic companies are based in the US. |
| • Each company's growth strategies and major | | | | • Spine, knee, and hip implants formed the largest |
| acquisitions and divestments relating to the CV | | | | orthopedic market segments in 2009, and accounted |
| devices market; | | | | for nearly $18.2bn sales. Surgical accessories used in |
| • Key partnerships and alliances formed by these | | | | orthopedic procedures represent the most fragmented |
| companies; | | | | market segment, followed by spinal devices. The |
| • Business-related strengths and weaknesses of | | | | orthobiologics segment has the least competition and |
| these companies, and insights into the opportunities and | | | | was also fastest growing segment. |
| threats facing them. | | | | • Regulatory pressure on the orthopedic market will |
| Key drivers and resistors to growth of leading CV | | | | significantly rise due to the impending review of the |
| device companies. | | | | PMN pathway, the Physician Payment Sunshine Act |
| Drivers | | | | and application of comparative effectiveness research |
| • Demographics – aging population | | | | (CER) information by buyers and payers. |
| • Preference for biologic implants increasing | | | | • Along with CER studies, the impending $20bn |
| • Growth in emerging markets | | | | medical device tax will add further pricing pressures. |
| • Physician preferences boosted by CME | | | | Key questions answered by this report |
| programs | | | | • What was the market value of the global |
| • Continued innovation | | | | orthopedic device industry in 2009? |
| Resistors | | | | • What are the global market values for the major |
| • Increasing pricing pressure from buyers and | | | | orthopedic device segments? |
| payers | | | | • What are the key trends observed in the |
| • Rising usage of comparative efficacy and health | | | | orthopedic device companies and what are the |
| economics data | | | | strategic responses that are taking shape? |
| • Regulatory demand for postmarketing surveillance | | | | • Who are the major players in the global |
| • Review of the PMN pathway in the US | | | | orthopedic device market? |
| • Medical device excise tax amounting to $20bn | | | | • What are the growth strategies of the leading |
| over the next 20 years | | | | orthopedic device companies? |
| Key benefits of reading this report | | | | • What are the strengths, weaknesses, |
| • Learn from the business operation strategies of | | | | opportunities and threats faced by the top 10 players? |
| the premier orthopedic device companies to target | | | | |